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Hematopoietic stem/progenitor cells (HSPCs) are used in clinical transplantation to restore hematopoietic function. Here we
review the role of the soluble matrix metalloproteinases MMP-2 and MMP-9, and membrane type (MT)1-MMP in modulating
processes critical to successful transplantation of HSPC, such as mobilization and homing. Growth factors and cytokines which
are employed as mobilizing agents upregulate MMP-2 and MMP-9. Recently we demonstrated that MT1-MMP enhances HSPC
migration across reconstituted basement membrane, activates proMMP-2, and contributes to a highly proteolytic bone marrow
microenvironment that facilitates egress of HSPC. On the other hand, we reported that molecules secreted during HSPC
mobilization and collection, such as hyaluronic acid and thrombin, increase MT1-MMP expression in cord blood HSPC and
enhance (prime) their homing-related responses. We suggest that modulation of MMP-2, MMP-9, and MT1-MMP expression has
potential for development of new therapies for more eﬃcient mobilization, homing, and engraftment of HSPC, which could lead
to improved transplantation outcomes.
1. Hematopoietic Stem/Progenitor
Cells(HSPCs)Transplantation
HSPCtransplantationisaclinicalprocedureinwhichHSPCs
capable of reconstituting normal bone marrow (BM) func-
tion are administered intravenously to a patient who has un-
dergone preparative regimens including chemotherapy and/
or irradiation. Approximately 60,000 autologous and alloge-
neic HSPC transplants are performed annually worldwide to
treat various cancers and diseases of the blood and immune
system [1]. During steady-state homeostasis, approximately
0.06% of BM HSPCs circulate continuously in the peripheral
blood(PB)[2],butthisnumbercanbeincreasedwiththeuse
of chemotherapeutic drugs (e.g., cyclophosphamide) and/or
growth factors and cytokines (e.g., granulocyte colony-
stimulating factor (G-CSF)) that “mobilize” HSPC from BM
into the PB [3]. Currently mobilized (m)PB HSPC collection
has almost replaced BM harvest for autologous and most
allogeneic transplantations because it is relatively easy to
collect by apheresis in an outpatient setting and because
engraftmentaftertransplantation is faster.G-CSFis the most
commonly used mobilizing agent in the clinic with regimens
using 10μg/kg/day for ﬁve days when used alone, or 10 to
14 days when used in combination with chemotherapeutic
agents [3]. Randomized trials of mPB transplantation have
shown that neutrophil and platelet engraftment generally
occurs at a median of 9–14 days compared to 21 days with
BM [4]. This has been attributed to the higher number of
HSPCcollectedandtransplanted.AlimitationofmPBHSPC
transplantation is that patients’ responses to G-CSF vary: 5–
10% of allogeneic normal donors mobilize poorly and up to
40% of autologous patients fail to mobilize depending on
their disease and the intensity/number of prior chemother-
apy regimens [5]. Hence, elucidation of the molecular mech-
anisms of HSPC mobilization could lead to more eﬃcient
mobilizing agents and development of better protocols.
An alternative source of HSPC is cord blood (CB) ob-
tained at the time of childbirth, after the umbilical cord has2 Biochemistry Research International
been detached from the newborn. Since the ﬁrst CB trans-
plant in 1988, more than 30,000 CB transplants have been
performed worldwide in pediatric and adult patients [1, 6].
CB has several advantages over BM and mPB as source of
HSPC for transplantation. CB contains lower numbers of
moreimmature,immunocompetentTcellsandthusrequires
less stringent HLA matching; this means that a mismatch at
one or two loci can be tolerated without signiﬁcant increase
in graft versus host disease (GvHD) or decrease in overall
survival [6, 7]. However, the main limitation of CB trans-
plantation is the low CD34+ cell dose available in one CB
unit which is generally insuﬃcient to support engraftment
in adult patients. Retrospective analyses of outcomes of CB
andBMtransplantationinadultshavereporteddelayedneu-
trophilengraftment:27dayswithCBversus18dayswithBM
andplateletengraftment:60dayswithCBversus29dayswith
BM [7]. Currently eﬀorts are being made to increase CB cell
dose in order to speed up engraftment and hematopoietic
recovery. Strategies to use more than one CB unit [7]o rt o
expand CB CD34+ cells ex vivo [8], however have met with
limited success. A more comprehensive knowledge of CB
HSPC biology and the mechanisms of their homing is ex-
pected to improve CB transplantation outcomes.
2. Mobilization of HSPC
Duringhomeostasis,continuoustraﬃcofHSPCbetweenthe
BM and PB contributes to normal hematopoiesis. The ability
to enhance these physiological processes and, for example,
enforce egress (mobilization) of HSPC from the BM to cir-
culation has been invaluable in clinical transplantation [9].
Several cytokines (G-CSF, granulocyte macrophage-CSF, Flt-
3 ligand, interleukin (IL)-8, and stem cell factor (SCF)/kit-
ligand) and chemokines (stromal cell-derived factor (SDF)-1
and GROβ) can trigger mobilization in varying degrees
[3, 10]. We recently demonstrated that G-CSF also increases
plasma hepatocyte growth factor (HGF) levels in mobilized
patients and expression of its receptor c-Met in HSPC and
myeloid cells, suggesting that GCSF-mediated HSPC mobi-
lization occurs in part through the HGF/c-Met axis [11].
Another important axis that inﬂuences mobilization is
the SDF-1/CXCR4 axis. This axis is essential for retention of
HSPC in the BM, and perturbation of the SDF-1 gradient in
theBMaswellasadecreaseintheresponsivenessofHSPCto
SDF-1 leads to mobilization [12].
The proteases carboxypeptidase M (CPM) [13]a n d
CD26 [14] cleave the C-terminus of SDF-1 resulting in at-
tenuated chemotactic responses of HSPC; moreover, G-CSF-
induced mobilization is impaired in CD26-deﬁcient mice
[14]. Desensitization of CXCR4 by the urokinase-mediated
plasminogen activation system during G-CSF-induced mo-
bilization has been demonstrated [15]. In murine studies,
SDF-1 concentration in the BM decreased following G-CSF
administration and correlated with mobilization, suggesting
that a physiological drop in SDF-1 level in the BM is a criti-
cal step in HSPC mobilization [12, 16]. A decrease in BM
SDF-1 levels has been reported to coincide with a peak of
proteolytic activity of neutrophil elastase (NE), cathepsin G
(CG), and matrix metalloproteinase (MMP)-9 [17]. Both
SDF-1 and CXCR4 are targets of degradation by NE, CG,
MMP-9,MMP-2,andmembranetype(MT)1-MMP[18–20]
and can be inactivated by proteolytic cleavage. The roles of
these MMPs will be discussed in detail in subsequent sec-
tions.
Recent studies have demonstrated that thrombolytic
agents such as microplasmin, tenecteplase, and recombinant
tissue plasminogen activator enhance G-CSF-induced mobi-
lizationinmurinemodels[21].Adhesionmoleculesalsoplay
an important role in the retention of HSPC in the BM. Very
late antigen (VLA)-4 is expressed by HSPC and its ligand,
vascular cell adhesion molecule (VCAM)-1, is constitutively
expressed by endothelial and stromal cells [22]. Disruption
of the VCAM-1/VLA-4 axis with a small molecule inhibitor
of VLA-4 resulted in the mobilization of more HSC over
basal levels [23]. CD44, a polymorphic integral membrane
glycoprotein, binds to several extracellular matrix (ECM)
components such as hyaluronic acid (HA), ﬁbronectin, and
collagen and mice treated with anti-CD44 antibody or
lacking CD44 exhibit impaired mobilization in response to
G-CSF [24].
Components of innate immunity also participate in G-
CSF-induced HSPC mobilization [25]. During G-CSF-in-
duced mobilization, the complement cascade (CC) is acti-
vated by the classical pathway. However, in the early steps of
the CC, C1q, C3, and its cleavage fragments C3a and
desArgC3a increase retention of HSPC in BM while in the
later steps of the CC, C5, and its cleavage fragments C5a and
desArgC5a enhance HSPC mobilization and their egress into
PB [26–28].
3. Homing of HSPC
The success of clinical HSPC transplantation relies on the in-
herentabilityoftransplantedHSPCtohomeeﬃcientlytothe
BM niche and engraft. Interactions between HSPC and their
niches that are disrupted during mobilization need to be re-
established during their homing to the BM and its repopula-
tion. Previously it was believed that mobilization and hom-
ingweremirrorimagesofeachother;however,emergingevi-
dence now suggests that this is not the case, although both
processesinvolvemanyofthesameadhesiveandchemotactic
interactions. The homing of HSPC to BM is a rapid process
occurring within hours after their transplantation and is a
prerequisite for their repopulation and engraftment [29].
Homing involves three consecutive steps: extravasation from
PBthroughtheBMendothelium,migrationthroughstroma,
and lodgement into niches.
The extravasation of circulating HSPC within the BM re-
quires a set of molecular interactions that mediates the rec-
ognition of circulating HSPC by the endothelium of BM
sinusoids [30]. The mechanisms of HSPC extravasation are
similar to those of leukocytes into inﬂamed tissues in that
they are mediated by adhesion molecules. The BM endothe-
lium constitutively expressing P-selectin, E-selectin, and
VCAM-1 mediates rolling and tethering of HSPC to the
blood vessel wall prior to their extravasation [31]. HSPC
expressing CD44 and VLA-4 receptors interact with their
cognate ligands on the endothelial surface. The coordinatedBiochemistry Research International 3
action of these adhesion molecules is triggered by SDF-1
presented at the surface of endothelial cells. SDF-1 medi-
ates activation of lymphocyte function-associated antigen-1,
VLA-4andVLA-5,convertingtherollingofHSPCintostable
arrest on the endothelium [32].
SDF-1—CXCR4 signalling is critical in the regulation of
HSPChoming,engraftment,andretentionintheBM.Block-
ade of CXCR4 was shown to inhibit HSPC homing and
engraftment, whereas overexpression of CXCR4 by CB and
mPB CD34+ cells leads to increased SDF-1 induced in vitro
migration and homing in NOD/SCID mouse models [33,
34]. We recently showed that mPB CD34+ cells that had
higher responsiveness to SDF-1 had high CXCR4 expression
and could compensate for a lower CD34+ cell dose in achiev-
ing faster hematopoietic engraftment after transplantation
[35]. SDF-1 binding to CXCR4 activates phosphatidylinos-
itol 3-kinase (PI3K), the phospholipase C-γ (PLC-γ)/protein
kinase C (PKC) cascade, and p44/42 mitogen-activated pro-
tein kinase (MAPK) [36]. SDF-1—CXCR4 signalling also
activates the atypical PKC subtype PKCζ which mediates cell
polarization, adhesion, MMP-9 secretion, and chemotaxis of
CD34+ cells [37]. Interactions mediated by the Rho family
GTPases (Rac, Rho, and Cdc42) have also been implicated
in HSPC homing and engraftment. Following engraftment,
deletion of Rac-1 and Rac-2 GTPases led to massive mobi-
lization of HSPC from BM. Knocking out Rac-1 signiﬁcantly
reduced migration towards SDF-1 and attenuated the hom-
ing of murine HSC to the endosteum, which is essential for
long-term HSC repopulation [38]. We previously demon-
strated that Rac-1 colocalization with CXCR4 in membrane
lipid rafts of HSPC promotes their in vivo homing in a
murine model [39]. Moreover, in vitro treatment of HSPC
with supernatants of leukapheresis products (SLPs) or their
components, such as C3a or platelet-derived microvesicles
(PMVs), modulates the SDF-1—CXCR4 axis and speed up
in vivo homing in murine models [39, 40].
Proteases regulate HSPC migration and tissue localiza-
tionandhavebeenshowntoalsoplayimportantfunctionsin
HSPC homing. The roles of proteolytic enzymes particularly
MMP-2, MMP-9, and MT1-MMP in this process will be
discussed in detail in subsequent sections.
4.MatrixMetalloproteinases
MMPs belong to a family of Zn2+-binding, Ca2+-dependent
endopeptidases whose essential function is proteolysis of the
ECM, a process that is required in several cellular processes
[41]. Currently, 24 human MMPs have been identiﬁed that
have structural similarities but vary in their expression pro-
ﬁles and substrate speciﬁcities. MMPs are classiﬁed based on
substrate recognition into stromelysins (MMP-3, MMP-10,
and MMP-11), matrilysins (MMP-7, MMP-26), gelatinases
(MMP-2 and MMP-9), and collagenases (MMP-1, MMP-8,
MMP-13, and MMP-14) [42]. Apart from ECM molecules,
MMPs act on a whole array of substrates including other
proteinases and MMPs, proteinase inhibitors, growth fac-
tors, cytokines, chemokines, cell surface receptors, and cell
adhesion molecules and regulate many processes such as cell
migration, proliferation, apoptosis, angiogenesis, tumor ex-
pansion, and metastasis [42–44]. The expression and func-
tion of MMPs are regulated at diﬀerent levels. Generally
expressed at low levels, MMPs are upregulated during tissue
remodeling, inﬂammation, wound healing, and cancer pro-
gression [45, 46]. They aresynthesized as latent enzymes that
are either secreted or membrane-anchored. Six MT-MMPs
have been identiﬁed so far, of which four, MT1-/MMP-14,
MT2-/MMP-15, MT3-/MMP-16, and MT5-/MMP-24, have
a transmembrane domain while the other two, MT4-/MMP-
17 and MT6-/MMP-25, have a glycosylphosphatidylinositol
domain [42]. Their membrane anchoring allows them to
carry out pericellular proteolysis. MMPs are activated by the
proteolytic release of the N-terminal propeptide domain.
Once active, they can be inhibited by endogenous tissue in-
hibitors ofmetalloproteinases (TIMPs),thereversion-induc-
ing cysteine-rich protein with Kazal motifs (RECK), and tis-
sue factor pathway inhibitor-2 as well as by plasma inhibitor
(α2-macroglobulin) [47, 48]. Therefore, a balance between
MMPs and their inhibitors is important to ECM remodeling
in the tissue and in HSPC migration.
The gelatinases MMP-2 and MMP-9 have been exten-
sivelystudiedincancerandotherdiseases.MMP-2issecreted
by ﬁbroblasts, endothelial cells, epithelial cells, and trans-
formed cells whereas MMP-9 is produced predominantly by
leukocytes [49]. MMP-2 and MMP-9 are required for phys-
iological processes such as ECM remodeling during growth
and development, inﬂammation, wound healing, angiogen-
esis, and leukocyte mobilization [41, 46]. They are also
involved in pathological processes such as cancer, inﬂamma-
tion, and neural and vascular degenerative diseases [45, 46].
Although MMP-2 and MMP-9 are secreted by cells in the
developing embryo, mice deﬁcient in these gelatinases are
viable. However, mice deﬁcient in MMP-2 exhibit defects in
developmentalangiogenesiswhereasmicedeﬁcientinMMP-
9 show delayed vascularization and ossiﬁcation resulting in
moderate skeletal abnormalities [49]. MMP-2 and MMP-9
are similar in many respects, but diﬀer in their glycosylation
pattern, activation, and substrate speciﬁcity. The 92kDa
MMP-9 has two glycosylation sites in the prodomain and the
catalytic domain whereas the 72kDa MMP-2 is a nonglyco-
sylated protein [42]. MMP-2 activation is a cell surface event
mediated by the formation of a ternary complex containing
MT1-MMP, TIMP-2, and proMMP-2 [42]. The N-terminal
domain of TIMP-2 binds to MT1-MMP whereas the C-
terminal domain binds the hemopexin domain of proMMP-
2. An adjacent MT1-MMP free of TIMP-2 subsequently
activates proMMP-2 by cleaving its propeptide domain. On
the other hand, MMP-9 activation is mediated by a prote-
olytic cascade involving MMP-3, MMP-2 and MMP-13 [42].
MMP-3 is activated by plasmin generated from plasminogen
by urokinase-type plasminogen activator (uPA) bound to its
receptor on the cell surface [42]. Similarly, MMP-2 activates
proMMP-13 which then activates proMMP-9 [50]. MMP-2
and MMP-9 share similar proteolytic activities and degrade
a number of ECM molecules such as gelatin, collagen types
IV, V, and XI, and laminin. In addition MMP-2 also degrades
collagen types I, II and III. Both also cleave several non-ECM
molecules such as SDF-1, tumor necrosis factor (TNF)-α,4 Biochemistry Research International
transforminggrowthfactor(TGF)-β,plasminogen,anduPA,
among many others [42–44].
MT1-MMP also plays important roles in both physiolog-
ical and pathological processes. Mice deﬁcient in MT1-MMP
exhibit craniofacial dysmorphism, dwarﬁsm, osteopenia, ﬁ-
brosis of soft tissues, arthritis, and premature death, empha-
sizing the function of MT1-MMP in ECM remodelling
during development [51]. On the other hand, elevated MT1-
MMP expression has been observed in a wide variety of
cancers including lung, breast, cervical, brain, liver, head,
and neck, indicating MT1-MMP’s role in tumor progression
and metastasis [45]. In addition, it has been implicated in
angiogenesis, bone development, atherosclerosis, inﬂamma-
tion, and wound healing [44] by virtue of its ability to de-
grade several ECM macromolecules including collagens,
laminins, ﬁbronectin, aggregan, and ﬁbronectin and to acti-
vate proMMP-2 and proMMP-13 [42, 44, 52]. MT1-MMP
cleaves CD44, processes αv integrin to its mature form, and
degrades tissue transglutaminase, thus modifying the imme-
diate cell environment and aﬀecting cellular functions in a
variety of ways [44]. MT1-MMP has a domain structure
composed of a propeptide region, catalytic domain, hinge
region,hemopexin-likedomain,andatypeItransmembrane
domain with a cytoplasmic tail at the C-terminus which an-
chors it to the cell surface [42]. MT1-MMP is also ex-
pressed in its latent form and cleavage of the propeptide
region by furin or related protein convertases renders it ac-
tive. Activation of MT1-MMP takes place in the trans-Golgi
network complex during secretion, and the enzyme is ex-
pressed in its active form at the cell surface [53]. Active
MT1-MMP is inhibited by RECK [54], TIMP-2, TIMP-3 and
TIMP-4butnotbyTIMP-1[48];however,TIMP-2hasadual
role. On the one hand it inhibits MT1-MMP and on the
other promotes activation of proMMP-2 [47]. At the cell
surface, the 60kDa active MT1-MMP molecule undergoes
self-proteolysis by removal of its catalytic domain which re-
sults in an inactive 44kDa species [55] .Ah i g hl e v e lo ft r u n -
cated MT1-MMP coincides with high proMMP-2 activation.
In migrating tumor cells, MT1-MMP localizes predomi-
nantly in the lamellipodia through its interaction with CD44
[56]. It has been reported that this interaction and the
consequent shedding of CD44 stimulate cell motility [57].
The hemopexin domain of MT1-MMP interacts with the
stem region of CD44 which interacts with F-actin through
its cytoplasmic domain. Binding of MT1-MMP with CD44
indirectlylinkstheproteinasetothecytoskeletonandthereby
enables its localization to the lamellipodia [58]. MT1-MMP
canbeinternalizedbybothclathrin-dependentandcaveolae-
dependent pathways, and recycled back to the surface, and
the internalization process is essential for the enzyme to
promote cell migration [58]. The redistribution of MT1-
MMP to sites of degradation, such as the lamellipodia of
endothelialcellsandtheinvadopodia oftumorcells,ishighly
complexandinvolvesadynamicinterplaybetweenendocytic
andexocyticprocesses[59].Inmostcelltypessurfaceexpres-
sion of MT1-MMP is low due to rapid endocytosis resulting
in intracellular accumulation of the proteinase in the early
and late endosomes. This dynamic regulation suggests that
the spatiotemporal recruitment of MT1-MMP to specialized
domains plays a critical role in its invasive properties [60].
Various growth factors, chemokines, and inﬂammatory me-
diators have been reported to modulate MT1-MMP expres-
sion in malignant and normal cells. In the ﬁbrosarcoma
cell line HT1080, Rac-1 modulation of MT1-MMP and its
processing to its 44kDa form correlated with proMMP-2
activation [61]. Furthermore, Rac-1 has been demonstrated
to promote hemophilic complex formation of MT1-MMP,
recruitment to the lamellipodia-rich cell surface, and subse-
quent proMMP-2 activation [62]. In Lewis lung carcinoma
cell line, type 1 insulin growth factor-1 increases invasiveness
of these cells through increased MT1-MMP expression via
the PI3K/AKT/mTOR pathway [63]. The SDF-1−CXCR4
axis promotes melanoma cell invasion and metastasis by
upregulating MT1-MMP through Rac-1 and RhoA-GTPases
[64]. Moreover, through activation of Rac-1 and its down-
stream eﬀector ERK1/2, SDF-1 intracellularly upregulates
MT1-MMP; however, when these cells were in contact with
Matrigel,aPI3K-dependenttransientredistributionofMT1-
MMP to the cell surface was observed [65]. In endothelial
cells, VEGF-mediated upregulation of MT1-MMP at the
mRNAleveloccursthroughtheMAPK/JNKpathway,where-
as protein expression is regulated by PI3K [66, 67]. MT1-
MMP clustering on the cell surface is dependent on cortical
actin polymerization which is regulated by PI3K, and this
clustering of MT1-MMP has been suggested to be more
important than its internalization [59]. In mesenchymal
stromal cells (MSCs), we reported that MT1-MMP mediates
their chemotactic migration towards SDF-1 and HGF [68].
Increased chemoinvasion of MSC through upregulation of
MT1-MMP by cytokines TGF-β,T N F - α, and IL-1 was also
reported [69]. In hematopoietic cells, MT1-MMP has been
demonstrated to mediate trans-endothelial migration of
monocytes,andtheinteractionofmonocyteswithﬁbronect-
inandendothelialligands,suchasVCAM-1andintracellular
cell adhesion molecule (ICAM)-1, increased MT1-MMP
clustering and localization into membrane protrusions or
lamellipodia [70].
5. MMPs inHSPCMobilization
MMPs have been traditionally considered to facilitate cell
migration by breaching basement membrane barriers com-
prised of ECM proteins. The mobilizing agent G-CSF indu-
ces neutrophil proliferation, activation, and degranulation
with the subsequent release of the serine proteases NE, CG,
and MMP-9 into the BM, making it a highly proteolytic
microenvironment [17, 71]. MMP-9 has been reported to
be elevated in plasma after mobilization with G-CSF or IL-
8[ 71, 72]. Mobilization is thought to occur predominantly
through the action of neutrophils and release of granulocytes
from the BM always precedes mobilization of HSPC [73].
However, HSPC themselves contribute to this process by
secreting MMP-2 and MMP-9 [74]. We have reported that
while BM HSPCs in steady-state do not secrete MMPs, upon
stimulation with G-CSF, among other growth factors and
cytokines, HSPCs secrete both MMP-2 and MMP-9 leading
to their enhanced migration through reconstituted basement
membrane (Matrigel) [74]. Both mature leukocytes as wellBiochemistry Research International 5
as immature CD34+ cells from in vivo G-CSF-mobilized PB
highly express MT1-MMP compared to their steady-state
(ss)BM and ssPB counterparts. Furthermore, cell surface
expression of MT1-MMP in in vivo mobilized polymor-
phonuclear cells (PMNs) and monocytes was 8 and 12 times
higher than in their respective ssPB counterparts. G-CSF
exerts its eﬀects on other signalling axes that also result in
upregulation of MMP-9 and MT1-MMP. For example, we
observed that HGF increases in the plasma of mobilized
patients and that G-CSF, through induction of HGF, upreg-
ulates MMP-9 and MT1-MMP expression in BM PMN [11].
Inaddition,activationoftheCCbyG-CSFtriggersaseriesof
reactions generating various bioactive peptides including the
C5 cleavage fragments (C5a and desArgC5a) which have been
shown to play an important role in mobilization [25, 75].
In particular, we recently demonstrated that C5a increases
MMP-9 and MT1-MMP expression in PMN and mononu-
clear cells (MNCs), contributing to a microenvironment that
is conducive to the egress of HSPC from the BM [28]. MT1-
MMP causes pericellular degradation by processing several
ECM components (such as gelatin, ﬁbronectin, laminin,
vitronectin, and ﬁbrillar collagens) [41, 43, 52]. This is
further substantiated by observation that G-CSF-induced
migration of MNC and HSPC through Matrigel (containing
collagen type IV, laminin, entactin) is MT1-MMP depen-
dent. MT1-MMP expressed by HSPC activates proMMP-2
secreted by BM stromal cells [76, 77]. Active MMP-2 could
subsequently initiate a cascade of activation of other MMPs
including MMP-9 and MMP-13, which not only degrade
the ECM but also disrupt adhesive interactions between
HSPC and their niches. One of the most potent of these
interactions is between SDF-1, produced by stromal cells,
including endothelial cells, and osteoblasts, and its receptor
CXCR4, expressed by HSPC. Recently, we demonstrated that
C5a, apart from upregulating MT1-MMP, decreases CXCR4
expressioninPMN,whichdisruptstheirchemotaxistowards
SDF-1. Moreover, this impaired chemoattraction is partially
restored by the potent MT1-MMP inhibitor EGCG (which
also inhibits proMMP-2 activation), suggesting that MT1-
MMP contributes towards reduced retention of HSPC in the
BM microenvironment [28].
In addition to matrix remodeling, MT1-MMP cleaves
adhesion molecules, such as CD44 and integrins, and che-
mokines such as SDF-1. Reduced retention of HSPC in the
BM during G-CSF-induced mobilization is also due to a
decrease in active SDF-1 in the BM which coincides with
peak proteolytic activity [12, 16]. SDF-1 can be cleaved and
inactivated by several proteases which are activated during
mobilization such as NE, CG, MMP-2 and MMP-9, CD26,
CPM, and MT1-MMP [13, 14, 17–20]. MT1-MMP cleavage
of SDF-1 results in loss of binding to CXCR4 and reduced
chemoattraction for CD34+ cells [18]. Therefore, during G-
CSF-induced mobilization, upregulation of MT1-MMP ex-
pression in HSPC has consequences that could lead to their
reduced retention in the BM and resultant egress into PB.
A low SDF-1 level in the BM during cytokine-induced
mobilization has been suggested to result from suppression
of SDF-1-producing osteoblasts, and although the mecha-
nismofthisphenomenonisnotcompletelyunderstood[78],
ithasbeensuggestedtooccurinlightofanobservedincrease
inosteoclastactivity[79].Activeboneremodelingtakesplace
during G-CSF mobilization, and increased cathepsin K and
MMP-9 secretion by osteoclasts has been implicated in high
bone turnover [79, 80]. Similarly, MT1-MMP also plays an
important role in bone remodeling as shown by the fact
that MT1-MMP−/− mice exhibit severe skeletal defects [51].
MT1-MMP is also known to be expressed by osteoclasts and
recently it was demonstrated that MT1-MMP was necessary
for macrophage fusion during multinucleated osteoclast
formation and diﬀerentiation [81]. Accordingly, 8-day-old
MT1-MMP−/− mice exhibited impaired osteoclast function,
which did not, however, result in increased bone mass
since osteoblast function is also compromised in these mice
[51, 81]. These results suggest that MT1-MMP could have
a dual role in bone development. Nevertheless, the role
of MT1-MMP in bone remodeling during G-CSF-induced
mobilization requires further investigation.
It was postulated that MT1-MMP expression in HSPC is
regulated by the endogenous inhibitor RECK and that high
MT1-MMP and low RECK levels in HSPC resulted in the
egressofBMprogenitorsinto circulation[54,77].Inarecent
publication, we provided evidence that MT1-MMP expres-
sion on the surface of HSPC is regulated by its incorpora-
tion into membrane lipid rafts, and that both MT1-MMP
expression and proMMP-2 activation are PI3K-dependent
[76]. Moreover, in co-cultures of ﬁbroblasts with BM CD34+
cells, proMMP-2 is not activated; however, pre-incubation
of CD34+ cells with G-CSF highly upregulated MT1-MMP,
which was then able to activate proMMP-2 in similar co-
cultures. Consistent with this, in co-cultures of stromal cells
with mPB CD34+ cells that had been transfected with MT1-
MMP siRNA, active MMP-2 was not detectable [76]. The
MT1-MMP activation of proMMP-2 in the BM microen-
vironment is important because active MMP-2 not only
initiates the activation of other MMPs that play a role in
matrix remodeling, but also inactivates SDF-1 and CXCR4
and adhesion molecules, processes which facilitate egress of
HSPC from BM niches across the ECM and subendothelial
membranes.
MT1-MMP promotes cell motility by pericellular ECM
degradation [41, 52, 53]. In this respect we demonstrated
the role of MT1-MMP in the migration of CD34+ cells and
MNC across reconstituted basement membrane as speciﬁc
inhibition of MT1-MMP by siRNA signiﬁcantly abrogated
their migration [76]. On the other hand, upregulation of
MT1-MMPexpressioninHSPCbyG-CSFcouldleadtotheir
reduced retention in the BM and enhanced egress into PB
[77]. The deﬁnitive proof of this would involve studies using
MT1-MMP−/− mice,butsuchmicehaveseveredevelopmen-
tal abnormalities resulting in their early death [51]; hence in
vivomobilizationexperimentsinMT1-MMPknockoutmice
are diﬃcult. However, these experiments have been carried
out in chimeric mouse models [77].
The initial cell response to cytokine or chemokine stim-
ulation is the reorganization of the actin cytoskeleton during
which several signalling pathways are activated. MT1-MMP
has been shown to be modulated by PI3K, MAPK, and Rho
familyGTPasesdependingonthecelltypeandstimulant[64,6 Biochemistry Research International
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Figure 1:(a)Administrationof amobilizingagent suchas G-CSF(1)expands thenumber of myeloidcells (neutrophils/granulocytes) inthe
bone marrow and promotes increased expression of proteolytic enzymes (including MMP-2, MMP-9, and MT1-MMP). (2) These enzymes
disrupt interactions that retain HSPC in their BM niches (e.g., SDF-1/CXCR4, VCAM-1/VLA-4, kit ligand/c-kitR, ECM). (3) Subsequently,
permeabilization of the endothelial barrier occurs with the granulocytes “paving the way” for the egress of HSPC. Chemoattractants in
the blood (primarily bioactive lipids such as sphingosine-1 phosphate (S1P) and hepatocyte growth factor (HGF)) further potentiate
mobilization of HSPC to the peripheral blood. (b) Priming molecules such as hyaluronic acid and thrombin (1) ampliﬁy the chemotactic
responses of HSPC via CXCR4 towards SDF-1 produced by bone marrow stromal cells and (2) accumulate MT1-MMP on the cell migration
front. (3) MT1-MMP promotes activation of MMP-2 that degrades ECM barriers allowing extravasation of HSPC across the sinusoid
endothelium. (4) HSPC highly expressing in CXCR4 attaches to the SDF-1-rich endosteal niches of the bone marrow.
82]. We demonstrated that although both PI3K and MAPK
areactivatedinhematopoieticcellsuponG-CSFstimulation,
MT1-MMP expression and proMMP-2 activation are only
PI3K dependent. Furthermore, inhibition of the PI3K-AKT
axis also inhibits cell polarization, co-localization of MT1-
MMP with F-actin, and trans-Matrigel migration of mPB
CD34+ cells [76]. Murine HSPC studies have shown that
cytokine-mediated lipid raft clustering activated the AKT-
FOXO signalling pathway, which is essential for entry into
cell cycle, and inhibition of lipid raft formation by MβCD
ledtorepressionofthispathwayandhibernation-likestateof
HSPC [83]. The recruitment of the regulatory PI3K subunit
p85 to lipid rafts after cytokine stimulation is required for
activation of the downstream eﬀectors of the PI3K-AKT axis
and is dependent on lipid raft integrity [84]. Consistent
with these ﬁndings, we showed that G-CSF-induced PI3K
activation in lipid rafts leads to reorganization of the actin
cytoskeleton, recruitment of MT1-MMP into lipid rafts, and
proMMP-2 activation [76], which increases the degradation
of basement membrane and interstitial matrix in the BM
microenvironment and eventually the egress of HSPC into
circulation as shown in Figure 1(a). Mobilizing signals such
as G-CSF expand the number of myeloid cells in the BM,
which secrete proteolytic enzymes (including MMP-2 and
MMP-9) that disrupt interactions that retain the HSPC
in the BM (e.g., SDF-1/CXCR4, VCAM-1/VLA-4, ECM).
Permeabilization of the endothelial barrier occurs with
granulocytes “paving the way” for HSPC. Chemoattractants
in the blood (e.g., bioactive lipids such as sphingosine 1-
phosphate, HGF) further facilitate egress into PB of HSPC
[73]( Figure 1(a)).
6. MMPs in HSPC Homing
MMPs degrade various ECM molecules and facilitate HSPC
transmigration across basement membrane barriers. SDF-1
and other growth factors induce the secretion of MMP-2 and
MMP-9, thus facilitating in vitro migration of HSPC across
reconstituted basement membrane towards SDF-1 [73].Biochemistry Research International 7
Incubation of CB-derived HSPC with SCF induces MMP-2
and MMP-9 secretion and homing in NOD/SCID mice [85].
We demonstrated that MT1-MMPmediates migration of CB
CD34+ cells and megakaryocytic progenitors towards an
SDF-1 gradient [86]. Recently another group reported, using
a chimeric mouse model, that engraftment levels of MT1-
MMP−/− c-Kit+ cells were signiﬁcantly lower than those of
wild-type cells, and inhibition of MT1-MMP by monoclonal
antibody attenuated homing of human HSPC in a NOD/
SCID mouse model [77].
WehavedemonstratedthatHSPCprimedbySLPortheir
components (ﬁbrinogen, ﬁbronectin, complement C1q,
complement C3a, PMV, HA, thrombin) respond better to
an SDF-1 gradient [26, 39, 40, 87, 88]. Furthermore, murine
HSPC that have been primed with C3a, PMV, or SLP before
transplantation engrafted faster in lethally irradiated mice
[39, 40, 87]. This priming eﬀect was due to increased incor-
poration of CXCR4 and Rac-1 GTPase into membrane lipid
rafts and to increased MMP-2 and MMP-9 secretion, indi-
cating that the SDF-1—CXCR4 axis cooperates with MMPs
during HSPC homing [39].
We recently investigated the eﬀects of two priming mole-
cules, HA and thrombin, on the modulation of MT1-MMP
expression and its activity [88]. First, we found that HA and
thrombin upregulated MT1-MMP expression in CB HSPC.
Secondly, HA- and thrombin-primed chemoinvasion of
HSPC towards a low SDF-1 gradient was MT1-MMP de-
pendent. It has been established that the SDF-1—CXCR4
axis promotes the chemotaxis not only of normal but also
oftumorcells[70,89].Forexample,thecoordinatedinterac-
tionofCXCR4andMT1-MMPisrequiredformelanomacell
metastasis to lungs [65]. CXCR4 was required for the initial
phases of melanoma cell chemotaxis and their arrival in the
lungs, whereas MT1-MMP was necessary for subsequent
invasion and dissemination of the tumor. We can therefore
speculatethatacoordinatedinteractionbetweenCXCR4and
MT1-MMP is also required by HSPC for their homing to the
BM. MT1-MMP expressed in CB HSPC (upregulated by HA
and thrombin), activates proMMP-2 secreted by endothelial
cells. Active MMP-2 could thereby participate in the extrava-
sation process and facilitate homing by activating other
MMPs and degrading ECM barriers [73]. In this respect,
MT1-MMP has been shown to facilitate trans-endothelial
migration of monocytes through clustering of MT1-MMP
at the lamellipodia upon contact with activated endothelial
cells or the immobilized endothelial ligands VCAM-1 and
ICAM-1 [70]. Priming of homing-related responses of CB
HSPC showed that HA and thrombin activated the PI3K-
AKT signalling axis and Rac-1 GTPase [88]. MT1-MMP
expression and proMMP-2 activation were dependent on
both these signalling pathways. We demonstrated that intra-
cellular crosstalk between these pathways leads to signal am-
pliﬁcation of a low SDF-1 gradient, leading to enhanced
MT1-MMP expression on the cell surface of CB HSPC and
increase chemoinvasion towards SDF-1 [88]. Thus, agents
such as HA and thrombin that positively regulate the
SDF-1—CXCR4 axis may also prime the homing-related
responses of HSPC by upregulating MT1-MMP. HSPCs then
attach/tether to and extravasate the sinusoid endothelium.
MT1-MMPpromotesactivationofproMMP-2thatdegrades
ECM barriers. HSPCs are chemoattracted to their BM niches
due to ampliﬁed chemotactic response towards SDF-1 pro-
duced by osteoblasts and stromal cells (Figure 1(b)).
7.TherapeuticStrategiestoImprove
Transplantation Outcomes
Accumulating evidence indicates an important role for
MMP-2,MMP-9,andMT1-MMPinHSPCmobilizationand
homing. In particular, modulation of MT1-MMP could be-
come a potential target for development of therapeutic strat-
egies that could improve transplantation outcomes. First,
critical to optimizing clinical mobilizing regimens is an
understanding of the molecular mechanisms that regulate
HSPC mobilization [73, 90, 91]. Such studies have already
ledtothedevelopmentofnewmobilizingagentsthatresulted
in a rapid collection of more HSPC for transplantation. For
example, recent use of Plerixafor (AMD3100) which revers-
ibly binds CXCR4 and disrupts SDF-1—CXCR4 interactions
has demonstrated that a combination of AMD3100 and G-
CSF results in greater mobilization eﬃcacy compared to G-
CSF alone [92, 93].
The main problem with G-CSF-induced mobilization is
the variable kinetics of mobilization as shown by the signiﬁ-
cant number of patients/donors who either mobilize poorly
or fail to mobilize. Recent ﬁndings indicate that positive reg-
ulation of MT1-MMP increases migration/mobilization of
HSPC, and hence the development of mobilizing agents that
increase MT1-MMP expression could enhance mobilization
eﬃciency. For example, cytokines such as HGF that upreg-
ulate MT1-MMP expression in HSPC [11] could also syn-
ergize with G-CSF and increase mobilization eﬃciencies in
patients who mobilize poorly with G-CSF alone. This could
be tested in a clinical setting following conﬁrmatory results
frommurinemodels.Ontheotherhand,potentialinhibitors
such as green tea polyphenol EGCG, which inhibits MT1-
MMP expression and proMMP-2 activation, and statins,
which like methyl-β-cyclodextrin disrupt lipid raft forma-
tion, could inhibit MT1-MMP incorporation into lipid rafts
and thereby negatively aﬀect HSPC mobilization. This could
result in lowering the number of HSPC collected, and there-
forewesuggestthatovercomingtheseinhibitoryeﬀectscould
improve transplantation outcomes.
Secondly, a successful transplantation outcome also de-
pends on the ability of a large number of intravenously in-
jected HSPC to rapidly ﬁnd their way to the BM. This has led
to the design of strategies to increase the number of HSPC
available by ex vivo expansion of HSPC before transplanta-
tion. Another strategy is to enhance the homing potential of
alimitednumberofHSPCbytheirexvivoexposuretoagents
suchasC3aandPMVthatprimetheirchemotacticresponses
by positively regulating the SDF-1—CXCR4 axis, as we
previously showed in murine models [40, 87]. Interestingly,
thisstrategyofexvivoexposureofCBHSPCtoC3aisalready
being evaluated in clinical trial [94]. Therefore we suggest
that other priming agents that enhance the responsiveness of
CB HSPC towards SDF-1 and upregulate MMPs expression8 Biochemistry Research International
could be used for ex vivo short-term treatment/priming of
CB HSPC and be evaluated in clinical trials.
Lastly, a better understanding of the molecular mecha-
nisms of HSPC migration is not only beneﬁcial for designing
novel therapeutic strategies discussed above but could also
beappliedtoenhancementofthehomingpropertiesofother
types of stem cells such as MSC which share common migra-
tion mechanisms.
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